2024-10-20 - Analysis Report
## Regeneron Pharmaceuticals Inc (REGN) Stock Analysis Report

**Company Overview:** Regeneron Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing life-transforming medicines for serious diseases.

**1. Performance Comparison to S&P 500 (VOO):**

* **Cumulative Return:** REGN: 88.97%, VOO: 137.88%
* **Return Difference:** -48.91%
* **Relative Divergence:** 28.36% (This indicates that REGN's performance is currently within the 28.36th percentile of its historical performance relative to VOO.)

**2. Recent Price Movements:**

* **Closing Price:** 990.68
* **5-Day Moving Average:** 1005.53
* **20-Day Moving Average:** 1023.85
* **60-Day Moving Average:** 1103.98

**3. Technical Indicators:**

* **RSI:** 26.43 (Indicates oversold conditions)
* **PPO:** 0.04 (Suggests a slightly positive momentum)
* **Delta_Previous_Relative_Divergence:** -27.24 (Shows a recent downward trend in relative performance)
* **Expected Return:** 0.0% (Indicates that over the long term (2+ years), REGN is expected to perform in line with S&P 500).

**4. Recent Earnings and Outlook:**

| Date        | EPS      | Revenue     |
|-------------|----------|-------------|
| 2024-08-01 | 13.25    | 3.55 B$     |
| 2024-05-02 | 6.70     | 3.15 B$     |
| 2023-11-02 | 9.48     | 3.36 B$     |
| 2023-08-03 | 9.05     | 3.16 B$     |
| 2024-08-01 | 9.05     | 3.16 B$     |

* **Most Recent Earnings:** 13.25 EPS and 3.55 B$ revenue, exceeding analyst estimates. 

**5. News and Recent Issues:**

* **Recent Market Outlook:** Analysts are generally optimistic about REGN's future prospects, citing strong drug pipeline, potential for new product launches, and solid financial performance. 
* **Analyst Opinions:**  Most analysts rate REGN as a "Buy" or "Hold" with a consensus price target slightly above current levels. 
* **Performance Highlights:** REGN has shown resilience in the face of market volatility, with a focus on R&D and innovation driving continued growth. 

**6.  Comprehensive Analysis:**

REGN is a biotechnology company with a strong track record of innovation and financial stability. Its recent earnings results were positive, exceeding analyst expectations. However, the stock has been underperforming relative to the broader market, as reflected in the lower cumulative return and relative divergence.  Technical indicators suggest oversold conditions and a potential short-term downward trend. The long-term outlook remains optimistic, with analysts expecting continued growth and innovation to drive value creation.

**7. Recommendations:**

* For long-term investors, REGN remains a promising investment opportunity with the potential for strong growth.
* However, given the recent underperformance and technical indicators, investors might consider a wait-and-see approach.
* Monitoring upcoming news and regulatory updates related to REGN's pipeline could provide valuable insights for decision-making.

**Disclaimer:** This analysis is for informational purposes only and should not be considered as financial advice.  Please consult with a qualified financial professional before making any investment decisions.